Thrombosis, platelets, microparticles and PAH: More than a clot

Drug Discovery Today

Volumn 19, Issue 8, 2014, Pages 1230-1235

  Lannan, Katie L ^a   Phipps, Richard P ^a,b   White, R James ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MIGRATION; DISEASE COURSE; ENDOTHELIAL MICROPARTICLE; ENDOTHELIUM CELL; HUMAN; IN VITRO STUDY; INFLAMMATION; INFLAMMATORY CELL; LUNG BLOOD VESSEL; LUNG CIRCULATION; LUNG EMBOLISM; LUNG VASCULAR RESISTANCE; PLATELET MICROPARTICLE; PULMONARY HYPERTENSION; REVIEW; SMOOTH MUSCLE FIBER; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE VOLUME; THROMBOCYTOPOIESIS; THROMBOSIS; BLOOD CLOTTING; MEMBRANE MICROPARTICLE; PATHOLOGY; PHYSIOLOGY;

BLOOD COAGULATION; BLOOD PLATELETS; CELL-DERIVED MICROPARTICLES; HUMANS; HYPERTENSION, PULMONARY; PLATELET ACTIVATION; THROMBOSIS;

EID: 84906314227     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.04.001     Document Type: Review

References (77)

1. R.T. Schermuly et al. Mechanisms of disease: pulmonary arterial hypertension Nat. Rev. Cardiol. 8 2011 443 455
2. G.G. Pietra et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the NHLBI Primary Pulmonary Hypertension Registry Circulation 80 1989 1198 1206
3. I.F. McMurtry et al. Rho kinase-mediated vasoconstriction in pulmonary hypertension Adv. Exp. Med. Biol. 661 2010 299 308
4. L.C. Price et al. Inflammation in pulmonary arterial hypertension Chest 141 2012 210 221
5. F. Perros et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension Am. J. Respir. Crit. Care Med. 185 2012 311 321
6. M. Humbert et al. Cellular and molecular pathobiology of pulmonary arterial hypertension J. Am. Col. Cardiol. 43 Suppl. 12 2004 13 24
7. V. Fuster et al. Primary pulmonary hypertension: natural history and the importance of thrombosis Circulation 70 1984 580 587
8. G.G. Pietra et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry Circulation 80 1989 1198 1206
9. C.A. W.N. Wagenvoort Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases Circulation 42 1970 1163 1184
10. C.A. Wagenvoort Lung biopsy specimens in the evaluation of pulmonary vascular disease Chest 77 1980 614 625
11. J. Bjornsson, and W.D. Edwards Primary pulmonary hypertension: a histopathologic study of 80 cases Mayo Clin. Proc. 60 1985 16 25
12. S.R. Johnson et al. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension Chest 130 2006 545 552
13. N. Mackman Role of tissue factor in hemostasis, thrombosis, and vascular development Arterioscler. Thromb. Vasc. Biol. 24 2004 1015 1022
14. R.J. White et al. Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension Am. J. Physiol. Lung Cell Mol. Physiol. 293 2007 L583 L590
15. D.F. Meoli, and R.J. White Thrombin induces fibronectin-specific migration of pulmonary microvascular endothelial cells: requirement of calcium-calmodulin dependent protein kinase II Am. J. Physiol. Lung Cell Mol. Physiol. 297 2009 L706 L714
16. B. Bakouboula et al. Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension Am. J. Respir. Crit. Care Med. 177 2008 536 543
17. P.R. Eisenberg et al. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension Circulation 82 1990 841 847
18. L.L. Schulman et al. Platelet activation and fibrinopeptide formation in pulmonary hypertension Chest 104 1993 1690 1693
19. A. Tournier et al. Calibrated automated thrombography demonstrates hypercoagulability in patients with idiopathic pulmonary arterial hypertension Thromb. Res. 126 2010 e418 e422
20. C.H. Welsh et al. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension Chest 110 1996 710 717
21. K. Huber et al. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension Am. J. Respir. Crit. Care Med. 150 1994 929 933
22. M. Miniati et al. Fibrin resistance to lysis in patients with pulmonary hypertension other than thromboembolic Am. J. Respir. Crit. Care Med. 181 2010 992 996
23. F. Sakamaki et al. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy Circulation 102 2000 2720 2725
24. D.B. Badesch et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines Chest 131 2007 1917 1928
25. A. Roman et al. Clinico-hemodynamic study and treatment of 44 patients with primary pulmonary hypertension Med. Clin. (Barc.) 118 2002 761 766
26. S.M. Kawut et al. New predictors of outcome in idiopathic pulmonary arterial hypertension Am. J. Cardiol. 95 2005 199 203
27. M. Ogata et al. Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension Jpn. Circ. J. 57 1993 63 69
28. S. Rich et al. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension N. Engl. J. Med. 327 1992 76 81
29. H. Frank et al. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension Chest 112 1997 714 721
30. O. Storstein et al. Primary pulmonary hypertension with emphasis on its etiology and treatment Acta Med. Scand. 179 1966 197 212
31. M. Delbeck et al. A role for coagulation factor Xa in experimental pulmonary arterial hypertension Cardiovasc. Res. 92 2011 159 168
32. I.D. Stuard et al. Microangiopathic hemolytic anemia and thrombocytopenia in primary pulmonary hypertension N. Engl. J. Med. 287 1972 869 870
33. P. Herve et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis Clin. Chest Med. 22 2001 451 458
34. E. Varol et al. Platelet indices in patients with pulmonary arterial hypertension Clin. Appl. Thromb. Hemost. 17 2011 E171 E174
35. S. Kamath et al. Platelet activation: assessment and quantification Eur. Heart J. 22 2001 1561 1571
36. I.C. Haznedaroǧlu et al. Thrombopoietin inside the pulmonary vessels in patients with and without pulmonary hypertension Platelets 13 2002 395 399
37. A.S. Weyrich, and G.A. Zimmerman Platelets in lung biology Annu. Rev. Physiol. 75 2013 569 591
38. B.W. Christman et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension N. Engl. J. Med. 327 1992 70 75
39. H.A. Ghofrani et al. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond Nat. Rev. Drug Discov. 5 2006 689 702
40. H.A. Ghofrani et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension J. Am. Col. Cardiol. 43 Suppl. 12 2004 68 72
41. G. Hagan, and J. Pepke-Zaba Pulmonary hypertension, nitric oxide and nitric oxide-releasing compounds Expert Rev. Respir. Med. 5 2011 163 171
42. J.R. Klinger et al. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension Am. J. Respir. Crit. Care Med. 188 2013 639 646
43. R.M. Tuder et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension Am. J. Resp. Crit. Care Med. 159 1999 1925 1932
44. M. Ferrantino, and R.J. White Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension Expert Opin. Pharmacother. 12 2011 2583 2593
45. S. Moncada et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation Nature 263 1976 663 665
46. N. Whittaker et al. The chemical structure of prostaglandin X (prostacyclin) Prostaglandins 12 1976 915 928
47. S.M. Kawut et al. von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension Chest 128 2005 2355 2362
48. A.A. Lopes et al. Plasma von Willebrand factor as a predictor of survival in pulmonary arterial hypertension associated with congenital heart disease Braz. J. Med. Biol. Res. 44 2011 1269 1275
49. J.K. Damås et al. Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells Circulation 110 2004 999 1005
50. R.P. Phipps Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system Proc. Natl. Acad. Sci. U. S. A. 97 2000 6930 6932
51. K.M. Fries et al. CD40 expression by human fibroblasts Clin. Immunol. Immunopathol. 77 1995 42 51
52. Y. Zhang et al. CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts J. Immunol. 160 1998 1053 1057
53. B.S. Beikmann et al. Serotonin uptake is largely mediated by platelets versus lymphocytes in peripheral blood cells ACS Chem. Neurosci. 4 2013 161 170
54. J.M. Launay et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension Nat. Med. 8 2002 1129 1135
55. N.F. Voelkel Appetite suppressants and pulmonary hypertension Thorax. 52 Suppl. 3 1997 63 67
56. S. Eddahibi et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension J. Clin. Invest. 108 2001 1141 1150
57. S. Ulrich et al. Platelet serotonin content and transpulmonary platelet serotonin gradient in patients with pulmonary hypertension Respiration 81 2011 211 216
58. P. Hervé et al. Increased plasma serotonin in primary pulmonary hypertension Am. J. Med. 99 1995 249 254
59. M. Aytekin et al. Abnormal platelet aggregation in idiopathic pulmonary arterial hypertension: role of nitric oxide Am. J. Physiol. Lung Cell Mol. Physiol. 302 2012 L512 L520
60. N.Y. Maeda et al. Increased tyrosine phosphorylation of platelet proteins including pp125(FAK) suggests endogenous activation and aggregation in pulmonary hypertension Clin. Appl. Thromb. Hemost. 11 2005 411 415
61. S.J. Shattil et al. Integrin signaling: the platelet paradigm Blood 91 1998 2645 2657
62. R. Rajkumar et al. Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension Am. J. Physiol. Heart Circ. Physiol. 298 2010 H1235 H1248
63. C. Léon et al. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice J. Clin. Invest. 104 1999 1731 1737
64. G.R. Sambrano et al. Role of thrombin signalling in platelets in haemostasis and thrombosis Nature 413 2001 74 78
65. I.M. Robbins et al. A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension Eur. Respir. J. 27 2006 578 584
66. S.M. Kawut et al. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT Circulation 123 2011 2985 2993
67. J. Ratajczak et al. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication Leukemia 20 2006 1487 1495
68. L.A. Hargett, and N.N. Bauer On the origin of microparticles: from "platelet" dust to mediators of intercellular communication Pulm. Circ. 3 2013 329 340
69. J. Sahler et al. A novel method for overexpression of peroxisome proliferator-activated receptor-γ in megakaryocyte and platelet microparticles achieves transcellular signaling J. Thromb. Haemost. 10 2012 2563 2572
70. N. Amabile et al. Microparticles: key protagonists in cardiovascular disorders Semin. Thromb. Hemost. 36 2010 907 916
71. H. Koga et al. Elevated levels of remnant lipoproteins are associated with plasma platelet microparticles in patients with type-2 diabetes mellitus without obstructive coronary artery disease Eur. Heart J. 27 2006 817 823
72. J. Rak Microparticles in cancer Semin. Thromb. Hemost. 36 2010 888 906
73. N. Amabile et al. Cellular microparticles in the pathogenesis of pulmonary hypertension Eur. Respir. J. 42 2013 272 279
74. P. Diehl et al. Enhanced microparticles in ventricular assist device patients predict platelet, leukocyte and endothelial cell activation Interact. Cardiovasc. Thorac. Surg. 11 2010 133 137
75. S. Nadaud et al. Small platelet microparticle levels are increased in pulmonary arterial hypertension Eur. J. Clin. Invest. 43 2013 64 71
76. E.I. Sinauridze et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets Thromb. Haemost. 97 2007 425 434
77. S.H. Visovatti et al. Increased CD39 nucleotidase activity on microparticles from patients with idiopathic pulmonary arterial hypertension PLoS One 7 2012 e40829